SCHEMBL2115641

SCHEMBL2115641

[CH2]CCCNC(=O)C1CCCC1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAAA Q02083 1/20 0.61
KEAP1 Q14145 1/20 0.53
NFE2L2 Q16236 1/20 0.53
EPHX1 P07099 1/20 0.50
SMN1; SMN2 Q16637 3/20 0.48
HSD17B10 Q99714 1/20 0.48
NAMPT P43490 1/20 0.47
NPC1 O15118 1/20 0.44
PKM P14618 1/20 0.44
EPHX2 P34913 1/20 0.44
RAB9A P51151 1/20 0.44
GNAI3 P08754 1/20 0.44
GNAO1 P09471 1/20 0.44
GNAI1 P63096 1/20 0.44
HDAC8 Q9BY41 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
KMT2A Q03164 3/20 0.42
GAA P10253 1/20 0.42
MEN1 O00255 1/20 0.42
CHRM1 P11229 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9035898 0.98 NAAA (0.64) NAAAKEAP1NFE2L2EPHX1SMN1; SMN2
SCHEMBL9036296 0.98 NAAA (0.64) NAAAKEAP1NFE2L2EPHX1SMN1; SMN2
SCHEMBL9034167 0.96 NAAA (0.56) NAAAKEAP1NFE2L2EPHX1SMN1; SMN2
SCHEMBL1689436 0.92 KMT2A (0.50) NAAAKEAP1NFE2L2EPHX1SMN1; SMN2
SCHEMBL8455292 0.91 NAAA (0.70) NAAAKEAP1NFE2L2EPHX1SMN1; SMN2
SCHEMBL9776358 0.91 NAAA (0.70) NAAAKEAP1NFE2L2EPHX1SMN1; SMN2
SCHEMBL9035265 0.88 NAAA (0.55) NAAAKEAP1NFE2L2EPHX1SMN1; SMN2
SCHEMBL1740262 0.86 NAAA (0.58) NAAAKEAP1NFE2L2EPHX1SMN1; SMN2
SCHEMBL9034554 0.86 NAAA (0.58) NAAAKEAP1NFE2L2EPHX1SMN1; SMN2
SCHEMBL17172545 0.83 NAAA (0.82) NAAAKEAP1NFE2L2EPHX1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8158794-B2 Hydroxyalkyl substituted imidazoquinoline compounds and methods 3M INNOVATIVE PROPERTIES COMPANY (US) 2012-04-17 US disclosed
US-20090069314-A1 Hydroxyalkyl Substituted Imidazoquinoline Compounds and Methods COLEY PHARMACEUTICAL GROUP, INC. (US) 2009-03-12 US disclosed
EP-1851218-A2 HYDROXYALKYL SUBSTITUTED IMIDAZOQUINOLINE COMPOUNDS AND METHODS 3M Innovative Properties Company (US) 2007-11-07 EP disclosed
WO-2006091567-A2 HYDROXYALKYL SUBSTITUTED IMIDAZOQUINOLINE COMPOUNDS AND METHODS COLEY PHARMACEUTICAL GROUP, INC. (US) 2006-08-31 WO disclosed
EP-0721454-A1 NEW PYRAZOLE DERIVATIVES AS ANGIOTENSIN II ANTAGONIST J. URIACH & CIA. S.A. (ES) 1996-07-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069314-A1 Hydroxyalkyl Substituted Imidazoquinoline Compounds and Methods IFNG, IRF3, IFNAR1 NAAA 2734/4885KEAP1 1442/4885NFE2L2 522/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.